The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections.
Journal
Current opinion in infectious diseases
ISSN: 1473-6527
Titre abrégé: Curr Opin Infect Dis
Pays: United States
ID NLM: 8809878
Informations de publication
Date de publication:
14 Aug 2024
14 Aug 2024
Historique:
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles. Sulbactam-durlobactam is a novel β-lactamase inhibitors combination specifically developed to target A. baumannii, including carbapenem-resistant strains. The purpose of this review is to assess the current evidence supporting the role of sulbactam-durlobactam in the management of A. baumannii infections. We summarize the available evidence regarding the pharmacokinetic and pharmacodynamic profiles of sulbactam-durlobactam from key in-vitro and in-vivo studies. Additionally, efficacy results from the Phase III randomized controlled trial and real-world data on sulbactam-durlobactam's use against severe A. baumannii infections are also discussed. Sulbactam-durlobactam is a promising addition to the treatment options for carbapenem-resistant A. baumannii infections. Ongoing research and vigilance are essential to monitor the development of in-vivo resistance, assess effectiveness across diverse patient populations, and explore potential synergistic combinations with other antimicrobials. Careful stewardship and comprehensive clinician education will be crucial to optimizing the clinical use of sulbactam-durlobactam.
Identifiants
pubmed: 39259710
doi: 10.1097/QCO.0000000000001059
pii: 00001432-990000000-00180
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Vazquez-Lopez R, Solano-Galvez SG, Juarez Vignon-Whaley JJ, et al. Acinetobacter baumannii resistance: a real challenge for clinicians. Antibiotics (Basel) 2020; 9:205.
Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics (Basel) 2020; 9:119.
Ma C, McClean S. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines (Basel) 2021; 9:570.
Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis 2018; 18:391–400.
Uwingabiye J, Frikh M, Lemnouer A, et al. Acinetobacter infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. Pan Afr Med J 2016; 23:191.
Falcone M, Tiseo G, Carbonara S, et al. Mortality attributable to bloodstream infections caused by different carbapenem-resistant Gram-negative bacilli: results from a nationwide study in Italy (ALARICO Network). Clin Infect Dis 2023; 76:2059–2069.
Lemos EV, de la Hoz FP, Einarson TR, et al. Carbapenem resistance and mortality in patients with Acinetobacter baumannii infection: systematic review and meta-analysis. Clin Microbiol Infect 2014; 20:416–423.
FDA. XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use. Prescribing information. 2023. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216974Orig1s000Correctedlbl.pdf.
Retsema JA, English AR, Girard AE. CP-45,899 in combination with penicillin or ampicillin against penicillin-resistant Staphylococcus, haemophilus influenzae, and bacteroides. Antimicrob Agents Chemother 1980; 17:615–622.
McLeod SM, Moussa SH, Hackel MA, et al. In vitro activity of sulbactam-durlobactam against Acinetobacter baumannii-calcoaceticus complex isolates collected globally in 2016 and 2017. Antimicrob Agents Chemother 2020; 64:e02534-19.
Barnes MD, Kumar V, Bethel CR, et al. Targeting multidrug-resistant Acinetobacter spp.: sulbactam and the diazabicyclooctenone beta-lactamase inhibitor ETX2514 as a novel therapeutic agent. mBio 2019; 10:e00159-19.
Naha A, Vijayakumar S, Lal B, et al. Genome sequencing and molecular characterisation of XDR Acinetobacter baumannii reveal complexities in resistance: Novel combination of sulbactam-durlobactam holds promise for therapeutic intervention. J Cell Biochem 2021; 122:1946–1957.
Shapiro AB, Gao N, Jahic H, et al. Reversibility of covalent, broad-spectrum serine beta-lactamase inhibition by the diazabicyclooctenone ETX2514. ACS Infect Dis 2017; 3:833–844.
Durand-Reville TF, Guler S, Comita-Prevoir J, et al. ETX2514 is a broad-spectrum beta-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii. Nat Microbiol 2017; 2:17104.
Findlay J, Poirel L, Bouvier M, et al. In vitro activity of sulbactam-durlobactam against carbapenem-resistant Acinetobacter baumannii and mechanisms of resistance. J Glob Antimicrob Resist 2022; 30:445–450.
Karlowsky JA, Hackel MA, McLeod SM, et al. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021. Antimicrob Agents Chemother 2022; 66:e0078122.
Nodari CS, Santos FF, Kurihara MNL, et al. In vitro activity of sulbactam/durlobactam against extensively drug-resistant Acinetobacter baumannii isolates belonging to South American major clones. J Glob Antimicrob Resist 2021; 25:363–366.
Seifert H, Muller C, Stefanik D, et al. In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii. J Antimicrob Chemother 2020; 75:2616–2621.
Principe L, Di Bella S, Conti J, et al. Acinetobacter baumannii resistance to sulbactam/durlobactam: a systematic review. Antibiotics (Basel) 2022; 11:1793.
Castanheira M, Mendes RE, Gales AC. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii-calcoaceticus complex. Clin Infect Dis 2023; 76: (Suppl 2): S166–S178.
O’Donnell J, Tanudra A, Chen A, et al. In vivo dose response and efficacy of the beta-lactamase inhibitor, durlobactam, in combination with sulbactam against the Acinetobacter baumannii-calcoaceticus complex. Antimicrob Agents Chemother 2024; 68:e0080023.
O’Donnell JP, Bhavnani SM. The pharmacokinetics/pharmacodynamic relationship of durlobactam in combination with sulbactam in in vitro and in vivo infection model systems versus Acinetobacter baumannii-calcoaceticus complex. Clin Infect Dis 2023; 76: (Suppl 2): S202–S209.
Lickliter JD, Lawrence K, O’Donnell J, et al. Safety, pharmacokinetics, and drug-drug interaction potential of intravenous durlobactam, a beta-lactamase inhibitor, in healthy subjects. Antimicrob Agents Chemother 2020; 64:e00071-20.
Rodvold KA, Gotfried MH, Isaacs RD, et al. Plasma and intrapulmonary concentrations of ETX2514 and sulbactam following intravenous administration of ETX2514SUL to healthy adult subjects. Antimicrob Agents Chemother 2018; 62:e01089-18.
Sagan O, Yakubsevitch R, Yanev K, et al. Pharmacokinetics and tolerability of intravenous sulbactam-durlobactam with imipenem-cilastatin in hospitalized adults with complicated urinary tract infections, including acute pyelonephritis. Antimicrob Agents Chemother 2020; 64:e01506-19.
O’Donnell J, Preston RA, Mamikonyan G, et al. Pharmacokinetics, safety, and tolerability of intravenous durlobactam and sulbactam in subjects with renal impairment and healthy matched control subjects. Antimicrob Agents Chemother 2019; 63:e00794-19.
O’Donnell J, Maloney K, Steidler M, et al. A randomized, double-blind, placebo- and positive-controlled crossover study of the effects of durlobactam on cardiac repolarization in healthy subjects. Clin Transl Sci 2021; 14:1423–1430.
Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, noninferiority clinical trial (ATTACK). Lancet Infect Dis 2023; 23:1072–1084.
McLeod SM, Miller AA, Rana K, et al. Clinical outcomes for patients with monomicrobial vs polymicrobial Acinetobacter baumannii-calcoaceticus complex infections treated with sulbactam-durlobactam or colistin: a subset analysis from a phase 3 clinical trial. Open Forum Infect Dis 2024; 11:ofae140.
Zaidan N, Hornak JP, Reynoso D. Extensively drug-resistant Acinetobacter baumannii nosocomial pneumonia successfully treated with a novel antibiotic combination. Antimicrob Agents Chemother 2021; 65:e0092421.
Tiseo G, Giordano C, Leonildi A, et al. Salvage therapy with sulbactam/durlobactam against cefiderocol-resistant Acinetobacter baumannii in a critically ill burn patient: clinical challenges and molecular characterization. JAC Antimicrob Resist 2023; 5:dlad078.
Tamma PD, Immel S, Karaba SM, et al. Successful treatment of carbapenem-resistant Acinetobacter baumannii meningitis with sulbactam-durlobactam. Clin Infect Dis 2024; ciae210.
Bassetti M, Vena A, Castaldo N, et al. Clinical evidence supporting cefiderol for serious Acinetobacter baumannii infections. Curr Opin Infect Dis 2022; (6):545–551.
Bassetti M, Vena A, Giacobbe DR. Management of nonfermenting gram-negative infections: a critique of the guidelines. Curr Opin Infect Dis 2023; 36:609–614.
Bassetti M, Castaldo N, Fantin A, et al. Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives. Curr Opin Infect Dis 2023; 36:615–622.
Dettori S, Portunato F, Vena A, et al. Severe infections caused by difficult-to-treat Gram-negative bacteria. Curr Opin Crit Care 2023; 29:438–445.